• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dual anti-HER2 therapy combined with chemotherapy as a novel neoadjuvant treatment option for locally advanced HER2-positive and microsatellite stable colon cancer.

作者信息

Pang Huayang, Chen Xiufeng, Yan Menghua, Sun Hao

机构信息

Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing 400030, China.

出版信息

Precis Clin Med. 2024 Dec 10;8(1):pbae033. doi: 10.1093/pcmedi/pbae033. eCollection 2025 Mar.

DOI:10.1093/pcmedi/pbae033
PMID:39790478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11715517/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efe6/11715517/6974cefe3461/pbae033fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efe6/11715517/6974cefe3461/pbae033fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efe6/11715517/6974cefe3461/pbae033fig1.jpg

相似文献

1
Dual anti-HER2 therapy combined with chemotherapy as a novel neoadjuvant treatment option for locally advanced HER2-positive and microsatellite stable colon cancer.双重抗HER2疗法联合化疗作为局部晚期HER2阳性且微卫星稳定结肠癌的一种新型新辅助治疗选择。
Precis Clin Med. 2024 Dec 10;8(1):pbae033. doi: 10.1093/pcmedi/pbae033. eCollection 2025 Mar.
2
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.采用 HER2/CEP17 FISH 比值预测曲妥珠单抗联合帕妥珠单抗新辅助治疗后 HER2+乳腺癌的病理完全缓解。
Oncologist. 2023 Feb 8;28(2):123-130. doi: 10.1093/oncolo/oyac247.
3
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.曲妥珠单抗新辅助化疗联合辅助曲妥珠单抗与单纯新辅助化疗治疗人表皮生长因子受体 2 阳性局部晚期乳腺癌患者（NOAH 试验）：一项具有平行人表皮生长因子受体 2 阴性队列的随机对照优效性试验。
Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.
4
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.曲妥珠单抗新辅助和辅助治疗人表皮生长因子受体 2 阳性局部晚期乳腺癌（NOAH）患者：一项随机对照优效试验的随访，该试验具有平行的人表皮生长因子受体 2 阴性队列。
Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20.
5
Clinical Outcomes of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 Breast Cancer Patients: A Single-Center Retrospective Study.人表皮生长因子受体2型乳腺癌患者新辅助治疗的临床结局：一项单中心回顾性研究
J Clin Med. 2022 Mar 5;11(5):1434. doi: 10.3390/jcm11051434.
6
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis.新辅助伊替木单抗和帕妥珠单抗联合紫杉烷类和卡铂（TCbIP）治疗局部晚期 HER2 阳性乳腺癌：一项前瞻性队列研究和倾向评分匹配分析。
BMC Cancer. 2024 Jul 22;24(1):877. doi: 10.1186/s12885-024-12654-3.
7
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.新辅助单药或双药 HER2 抑制治疗联合化疗方案对可手术局部晚期乳腺癌患者病理完全缓解的影响：随机试验的敏感性分析。
Cancer Treat Rev. 2014 Aug;40(7):847-56. doi: 10.1016/j.ctrv.2014.05.001. Epub 2014 May 15.
8
Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.加拿大新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎性或早期HER2阳性乳腺癌的成本效益分析。
J Med Econ. 2015 Mar;18(3):173-88. doi: 10.3111/13696998.2014.979938. Epub 2014 Nov 10.
9
Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review.新辅助吡咯替尼联合曲妥珠单抗及长春瑞滨治疗初始对HP方案耐药的HER2阳性局部晚期乳腺癌患者：1例病例报告及文献复习
Gland Surg. 2023 Feb 28;12(2):317-323. doi: 10.21037/gs-22-751. Epub 2023 Feb 27.
10
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer.HER2阳性乳腺癌中使用双抗HER2疗法进行新辅助化疗的真实世界数据。
BMC Cancer. 2024 Jan 25;24(1):134. doi: 10.1186/s12885-024-11871-0.

本文引用的文献

1
Use of trastuzumab and pertuzumab with FOLFOXIRI as neoadjuvant therapy for HER2-positive resectable metastatic colorectal cancer: The first case report.曲妥珠单抗和帕妥珠单抗联合FOLFOXIRI作为HER2阳性可切除转移性结直肠癌新辅助治疗的应用：首例病例报告。
Asian J Surg. 2024 Jul 24. doi: 10.1016/j.asjsur.2024.07.136.
2
HER-2 directed therapies across gastrointestinal tract cancers - A new frontier.曲妥珠单抗治疗消化道肿瘤——新领域。
Cancer Treat Rev. 2024 Sep;129:102789. doi: 10.1016/j.ctrv.2024.102789. Epub 2024 Jun 21.
3
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
《结肠癌临床实践指南（第 3.2024 版）》，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2024 Jun;22(2 D). doi: 10.6004/jnccn.2024.0029.
4
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.局部晚期错配修复缺陷型结直肠癌的新辅助免疫治疗。
N Engl J Med. 2024 Jun 6;390(21):1949-1958. doi: 10.1056/NEJMoa2400634.
5
[Neoadjuvant strategy for locally advanced colorectal cancer based organ preservation].基于器官保留的局部晚期结直肠癌新辅助治疗策略
Zhonghua Wei Chang Wai Ke Za Zhi. 2024 Apr 25;27(4):416-423. doi: 10.3760/cma.j.cn441530-20231231-00235.
6
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.图卡替尼联合曲妥珠单抗治疗化疗耐药、HER2 阳性、RAS 野生型不可切除或转移性结直肠癌（MOUNTAINEER）：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X.
7
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.曲妥珠单抗-德鲁替康（DS-8201）治疗人表皮生长因子受体 2（HER2）表达的转移性结直肠癌（DESTINY-CRC01）患者：一项多中心、开放标签、Ⅱ期临床试验。
Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4.
8
Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.下一代测序检测 ERBB2 扩增可预测结直肠癌的 HER2 表达。
Am J Clin Pathol. 2019 Jun 5;152(1):97-108. doi: 10.1093/ajcp/aqz031.
9
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.针对结直肠癌中的 HER2：ERBB2 和 ERBB3 扩增和短变异突变的全景。
Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16.